+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Slow CYP2D6 metabolizer phenotype associated with death in a toddler receiving a therapeutic dose of dextromethorphan

Slow CYP2D6 metabolizer phenotype associated with death in a toddler receiving a therapeutic dose of dextromethorphan

Pediatric Research 41(4 PART 2): 55A

(PDF emailed within 1 workday: $29.90)

Accession: 033411960

Download citation: RISBibTeXText

Related references

Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion. Therapeutic Drug Monitoring 24(3): 436-437, 2002

Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype. Breast 23(4): 400-406, 2015

A rare insertion of T226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15. Pharmacogenetics 6(3): 269-272, 1996

A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype. Pharmacogenetics 9(3): 287-293, 1999

Prevalence of the slow metabolizer phenotype and single dose pharmacokinetics of desloratadine in a population of healthy adults. Clinical Pharmacology & Therapeutics 75(2): P9, February, 2004

Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?. Pharmacogenetics 11(1): 45-55, 2001

Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study. Journal of Pain and Symptom Management 36(1): 92-96, 2008

Determination of dextromethorphan metabolizer phenotype in healthy volunteers. European Journal of Clinical Pharmacology 36(3): 315-318, 1989

Rare CYP2D6 alleles associated with the poor metabolizer phenotype. European Journal of Clinical Pharmacology 52(SUPPL ): A72, 1997

Dextromethorphan-induced near-fatal suicide attempt in a slow metabolizer at cytochrome P450 2D6. American Journal of Geriatric PharmacoTherapy 5(2): 162-165, 2007

Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response. Pharmacotherapy 17(6): 1305-1310, 1997

CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metabolism and Disposition: the Biological Fate of Chemicals 34(4): 563-569, 2006

Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metabolism and Disposition 30(5): 595-601, 2002